{"url_path":"/sec/pstv/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","accession_number":"0001193125-26-226978","cik":"0001095981","ticker":"PSTV","issuer_name":"PLUS THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1095981/0001193125-26-226978-index.html","primary_entity_key":"0001095981","primary_entity_name":"PLUS THERAPEUTICS, INC."},"word_count":261,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\n2(a): Unregistered Sales of Equity Securities and Use of Proceeds\n\nNone.\n\n2(b): Use of Proceeds from Registered Securities\n\nNone.\n\n2(c): Purchases of Equity Securities\n\nThe following table provides certain information with respect to the Company's purchases of its common stock for the three months ended March 31, 2026.\n\n \n\n \n\n \n\nCompany Purchases of Common Stock\n\n \n\nPeriod\n\n \n\nTotal Number of Shares Purchased\n\n \n\n \n\nAverage Price Paid per Share\n\n \n\n \n\nTotal Number of Shares Purchased As Part of Publicly Announced Plans or Programs\n\n \n\n \n\nApproximate Dollar Value of Shares That May Yet Be Purchased Under Plans or Programs(1)\n\n \n\nJanuary 1 - 31, 2026\n\n \n\n \n\n272,821\n\n \n\n \n\n$\n\n16.50\n\n \n\n \n\n \n\n272,821\n\n \n\n \n\n$\n\n-\n\n \n\nFebruary 1 - 28, 2026\n\n \n\n \n\n-\n\n \n\n \n\n$\n\n-\n\n \n\n \n\n \n\n-\n\n \n\n \n\n$\n\n-\n\n \n\nMarch 1 - 31, 2026\n\n \n\n \n\n-\n\n \n\n \n\n$\n\n-\n\n \n\n \n\n \n\n-\n\n \n\n \n\n$\n\n-\n\n \n\nTotal\n\n \n\n \n\n272,821\n\n \n\n \n\n$\n\n-\n\n \n\n \n\n \n\n272,821\n\n \n\n \n\n$\n\n-\n\n \n\n(1)\nOn March 4, 2025, the Company entered into the March 2025 SPA with the March 2025 Private Placement Purchasers for the March 2025 Private Placement . On June 17, 2025, the Company and the Purchasers entered into the Letter Agreement with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement and provided for the return and cancellation of Private Placement Shares and Pre-Funded Warrants. The Private Placement Shares and Pre-Funded Warrants were repurchased by the Company pursuant to the Letter Agreement. Refer to Note 12 Stockholders’ Equity in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Letter Agreement."}